Rafael Santana-Davila
@valdesan.bsky.social
Thoracic, Head and Neck oncologist #medsky #oncsky
Fred Hutch Cancer Center. @fredhutch.bsky.social
University of Washington.
Fred Hutch Cancer Center. @fredhutch.bsky.social
University of Washington.
Reposted by Rafael Santana-Davila
This is bad. The best way to have said this was that “some patients with cancer we know cure is not an option, the intent of treatment is to help them live better and live longer. in your case, there is hope that cancer can be eliminated, and therefore treatment is with curative intent”
July 26, 2025 at 2:48 PM
This is bad. The best way to have said this was that “some patients with cancer we know cure is not an option, the intent of treatment is to help them live better and live longer. in your case, there is hope that cancer can be eliminated, and therefore treatment is with curative intent”
Would also mandate that crossover is allowed.
June 1, 2025 at 3:18 PM
Would also mandate that crossover is allowed.
Does this have to be compared to chemo? And if so is cpi needed in the control arm?
June 1, 2025 at 2:46 PM
Does this have to be compared to chemo? And if so is cpi needed in the control arm?
Reposted by Rafael Santana-Davila
Published in JCO today ascopubs.org/doi/10.1200/...
Zipalertinib in Patients With <i>EGFR</i> Exon 20 Insertion-Positive NSCLC Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab
PURPOSETo evaluate the safety and efficacy of zipalertinib, an irreversible epidermal growth
factor receptor (EGFR) inhibitor, in pretreated patients with non-small cell lung
cancer (NSCLC) harboring ...
ascopubs.org
June 1, 2025 at 2:11 PM
Published in JCO today ascopubs.org/doi/10.1200/...
Zongertiniv is few steps ahead. Data loos similar. What phase 3 studies do we need to make targeted therapy the first line soc?
June 1, 2025 at 2:43 PM
Zongertiniv is few steps ahead. Data loos similar. What phase 3 studies do we need to make targeted therapy the first line soc?